Shilpa Medicare Limited receives DCG(i) approval for '2-Deoxy-2-Glucose'

Shilpa Medicare Limited has received DCG(i) approval for 2-Deoxy2-Glucose (Bulk & Oral Powder). The bulk is manufactured by Shilpa Medicare Limited, API facility in Raichur,' Karnataka. The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana.

2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients. The product will be available with a brand name '2-DGSHIL'.

Shares of Shilpa Medicare Ltd. was last trading in BSE at Rs. 567 as compared to the previous close of Rs. 572.65. The total number of shares traded during the day was 12562 in over 688 trades.

The stock hit an intraday high of Rs. 583.45 and intraday low of 567. The net turnover during the day was Rs. 7222127.

Source : Equity Bulls

Keywords